Nancy A. Simonian - Oct 31, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: President & CEO, Director
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Oct 31, 2023
Transactions value $: -$29,750
Form type: 4
Date filed: 11/2/2023, 04:54 PM
Previous filing: Jun 2, 2023
Next filing: Dec 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Options Exercise		+40.1K	+54.65%		114K	Oct 31, 2023	Direct	F1
transaction	SYRS	Common Stock	Tax liability	-$29.8K	-13.4K	-11.8%	$2.22	100K	Nov 1, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Restricted Stock Units	Options Exercise	$0	-40.1K	-50%	$0.00	40.1K	Oct 31, 2023	Common Stock	40.1K		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	Represents shares used to cover tax withholding on a restricted stock unit release.
F3	Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4	Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.